Theravance Biopharma (TBPH) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Theravance Biopharma, Inc. Reports Second Quarter 2016 Financial Results and Provides Business Update
August 8, 2016 4:15 PM EDTDUBLIN, IRELAND -- (Marketwired) -- 08/08/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported financial results for the second quarter ended June 30, 2016. Revenue for the second quarter 2016 was $5.5 million. The second quarter operating loss excluding share-based compensation was $37.6 million, or $47.5 million including share-based compensation of $9.9 million. Cash, cash equivalents, and marketable securities totaled $302.0 million as of June 30, 2016. The quarter-end cash balance excludes $35.1 million in receivables from collaborative arrangements. Also excluded from quarter-end cash is a $15.0 million upfront payment expected in the third quarter from Takeda Pharmaceuticals associated with the TD-8954 license... More
